Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/19071
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorris, RW-
dc.contributor.authorCooper, JA-
dc.contributor.authorShah, T-
dc.contributor.authorWong, A-
dc.contributor.authorDrenos, F-
dc.contributor.authorEngmann, J-
dc.contributor.authorMcLachlan, S-
dc.contributor.authorJefferis, B-
dc.contributor.authorDale, C-
dc.contributor.authorHardy, R-
dc.contributor.authorKuh, D-
dc.contributor.authorBen-Shlomo, Y-
dc.contributor.authorWannamethee, SG-
dc.contributor.authorWhincup, PH-
dc.contributor.authorCasas, JP-
dc.contributor.authorKivimaki, M-
dc.contributor.authorKumari, M-
dc.contributor.authorTalmud, PJ-
dc.contributor.authorPrice, JF-
dc.contributor.authorDudbridge, F-
dc.contributor.authorHingorani, AD-
dc.contributor.authorHumphries, SE-
dc.date.accessioned2019-09-06T10:08:08Z-
dc.date.available2016-10-15-
dc.date.available2019-09-06T10:08:08Z-
dc.date.issued2016-06-30-
dc.identifier.citationHeart, 2016, 102 (20), pp. 1640 - 1647en_US
dc.identifier.issn1355-6037-
dc.identifier.issnhttp://dx.doi.org/10.1136/heartjnl-2016-309298-
dc.identifier.issn1468-201X-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/19071-
dc.description.abstractObjective We investigated discrimination and calibration of cardiovascular disease (CVD) risk scores when genotypic was added to phenotypic information. The potential of genetic information for those at intermediate risk by a phenotype-based risk score was assessed. Methods Data were from seven prospective studies including 11..851 individuals initially free of CVD or diabetes, with 1444 incident CVD events over 10â..years' follow-up. We calculated a score from 53 CVD-related single nucleotide polymorphisms and an established CVD risk equation QRISK-2' comprising phenotypic measures. The area under the receiver operating characteristic curve (AUROC), detection rate for given false-positive rate (FPR) and net reclassification improvement (NRI) index were estimated for gene scores alone and in addition to the QRISK-2 CVD risk score. We also evaluated use of genetic information only for those at intermediate risk according to QRISK-2. Results The AUROC was 0.635 for QRISK-2 alone and 0.623 with addition of the gene score. The detection rate for 5% FPR improved from 11.9% to 12.0% when the gene score was added. For a 10-year CVD risk cut-off point of 10%, the NRI was 0.25% when the gene score was added to QRISK-2. Applying the genetic risk score only to those with QRISK-2 risk of 10%-<20% and prescribing statins where risk exceeded 20% suggested that genetic information could prevent one additional event for every 462 people screened. Conclusion The gene score produced minimal incremental population-wide utility over phenotypic risk prediction of CVD. Tailored prediction using genetic information for those at intermediate risk may have clinical utility.en_US
dc.format.extent1640 - 1647-
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.titleMarginal role for 53 common genetic variants in cardiovascular disease predictionen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1136/heartjnl-2016-309298-
dc.relation.isPartOfHeart-
pubs.issue20-
pubs.publication-statusPublished-
pubs.volume102-
dc.identifier.eissn1468-201X-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf693.09 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.